Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2020
LYON, France , April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F
LYON, France and CAMBRIDGE, Mass. , March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019
Conference call and webcast on Tuesday, March 17 at 1:30 pm CET/8:30 am ET More than two-thirds of the expected number of patients have been enrolled in the TRYbeCA‑1 Phase 3 clinical trial Cash position of €73.2 million ( $82.2 million ) at the end of 2019 LYON, France and CAMBRIDGE, Mass.
View HTML
Toggle Summary ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors
LYON, France and CAMBRIDGE, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the appointment of Melanie
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle May 6, 2020

Business Update and Financial Highlights for the 1st Quarter of 2020 (after U.S. market close)

Summary Toggle May 7, 2020 at 8:30 AM EDT

Erytech Pharma 1st Quarter of 2020 Conference Call and Webcast

Summary Toggle Sep 21, 2020

Business Update and Financial Highlights for the 2nd Quarter of 2020 (after U.S. market close)

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top